154 related articles for article (PubMed ID: 22932087)
1. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
[TBL] [Abstract][Full Text] [Related]
2. Defining a molecular phenotype for benign and malignant parathyroid tumors.
Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
[TBL] [Abstract][Full Text] [Related]
3. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions.
Saggiorato E; Bergero N; Volante M; Bacillo E; Rosas R; Gasparri G; Orlandi F; Papotti M
Am J Clin Pathol; 2006 Jul; 126(1):59-66. PubMed ID: 16753595
[TBL] [Abstract][Full Text] [Related]
5. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases.
Bergero N; De Pompa R; Sacerdote C; Gasparri G; Volante M; Bussolati G; Papotti M
Hum Pathol; 2005 Aug; 36(8):908-14. PubMed ID: 16112008
[TBL] [Abstract][Full Text] [Related]
7. The Role of Parafibromin, Galectin-3, HBME-1,
and Ki-67 in the Differential Diagnosis of Parathyroid Tumors.
Karaarslan S; Yurum FN; Kumbaraci BS; Pala EE; Sivrikoz ON; Akyildiz M; Bugdayci MH
Oman Med J; 2015 Nov; 30(6):421-7. PubMed ID: 26675091
[TBL] [Abstract][Full Text] [Related]
8. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
9. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
[TBL] [Abstract][Full Text] [Related]
10. Loss of parafibromin expression in a subset of parathyroid adenomas.
Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism.
Ozolins A; Narbuts Z; Vanags A; Simtniece Z; Visnevska Z; Akca A; Wirowski D; Gardovskis J; Strumfa I; Goretzki PE
Langenbecks Arch Surg; 2016 Nov; 401(7):943-951. PubMed ID: 26658808
[TBL] [Abstract][Full Text] [Related]
12. Molecular Characteristics of Large Parathyroid Adenomas.
Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
[TBL] [Abstract][Full Text] [Related]
13. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
Truran PP; Johnson SJ; Bliss RD; Lennard TW; Aspinall SR
World J Surg; 2014 Nov; 38(11):2845-54. PubMed ID: 25002250
[TBL] [Abstract][Full Text] [Related]
14. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
[TBL] [Abstract][Full Text] [Related]
15. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
[TBL] [Abstract][Full Text] [Related]
16. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic significance of parafibromin expression in parathyroid carcinoma.
Gao Y; Wang P; Lu J; Pan B; Guo D; Zhang Z; Wang A; Zhang M; Sun J; Wang W; Liang Z
Hum Pathol; 2022 Sep; 127():28-38. PubMed ID: 35654240
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic implications of parafibromin immunohistochemistry in parathyroid carcinomaT.
Pyo JS; Cho WJ
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30926677
[TBL] [Abstract][Full Text] [Related]
20. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.
Woodard GE; Lin L; Zhang JH; Agarwal SK; Marx SJ; Simonds WF
Oncogene; 2005 Feb; 24(7):1272-6. PubMed ID: 15580289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
